Molecular Dx Labs Fret Over Medicare Payment Setting, Or, In Some Cases, Lack Thereof

The industry’s angst is growing several months after CMS announced a plan to task contractors with independently setting regional payments for more than 100 new molecular diagnostic codes. A breakdown in the process so far, stakeholders say, could have a lasting impact on small, venture-backed labs.

More from Policy & Regulation

More from Medtech Insight